Acasti Pharma Inc. (NASDAQ:ACST) and Abeona Therapeutics Inc. (NASDAQ:ABEO), both competing one another are Biotechnology companies. We will contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Acasti Pharma Inc. and Abeona Therapeutics Inc.

Profitability

Table 2 has Acasti Pharma Inc. and Abeona Therapeutics Inc.’s net margins, return on equity and return on assets.

Analyst Ratings

The Recommendations and Ratings for Acasti Pharma Inc. and Abeona Therapeutics Inc. are featured in the next table.

On the other hand, Abeona Therapeutics Inc.’s potential upside is 285.21% and its consensus target price is $25.

Insider and Institutional Ownership

Acasti Pharma Inc. and Abeona Therapeutics Inc. has shares owned by institutional investors as follows: 3.77% and 68.7%. About 8.49% of Acasti Pharma Inc.’s share are owned by insiders. Comparatively, Abeona Therapeutics Inc. has 33.45% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Acasti Pharma Inc.’s stock price has bigger growth than Abeona Therapeutics Inc.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. Acasti Pharma Inc. was incorporated in 2002 and is based in Laval, Canada.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companyÂ’s lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.